Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 20, Issue 45, 2014, Pages 17107-17114

  Pacifico, Lucia ^a   Bonci, Enea ^a   Marandola, Lidia ^a   Romaggioli, Sara ^a   Bascetta, Stefano ^a   Chiesa, Claudio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Children; Intestinal permeability; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Zonulin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INSULIN; PROTEIN; UNCLASSIFIED DRUG; ZONULIN; BIOLOGICAL MARKER; CHOLERA TOXIN;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CASE CONTROL STUDY; CHILD; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; HEPATITIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; PUBERTY; ADOLESCENT; BIOPSY; BLOOD; CHILDHOOD OBESITY; COMPLICATION; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; UPREGULATION;

ADOLESCENT; AGE FACTORS; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; CHILD; CHOLERA TOXIN; FEMALE; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PEDIATRIC OBESITY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84917736907     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i45.17107     Document Type: Article

References (31)

1. Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am 2011; 58: 1375-1392, x [PMID: 22093857 DOI: 10.1016/j.pcl.2011]
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]
3. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10: 627-636 [PMID: 23958599]
4. Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis 2014; 18: 59-71 [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002]
5. Miele L, Marrone G, Lauritano C, Cefalo C, Gasbarrini A, Day C, Grieco A. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des 2013; 19: 5314-5324 [PMID: 23432669]
6. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
7. Fasano A. Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin. Ann N Y Acad Sci 2000; 915: 214-222 [PMID: 11193578 DOI: 10.1111/ j.1749-6632.2000.tb05244]
8. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000; 113 Pt 24: 4435-4440 [PMID: 11082037]
9. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, Antalis TM, Vogel SN, Zhao A, Yang S, Arrietta MC, Meddings JB, Fasano A. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 2009; 106: 16799-16804 [PMID: 19805376 DOI: 10.1073/pnas.0906773106]
10. El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, Catassi C, Fasano A. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 2002; 123: 1607-1615 [PMID: 12404235 DOI: 10.1053/gast.2002.36578]
11. Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, Sapone A, Thakar M, Iacono G, Carroccio A, DAgate C, Not T, Zampini L, Catassi C, Fasano A. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006; 41: 408-419 [PMID: 16635908 DOI: 10.1080/00365520500235334]
12. Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, Goldblum SE. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000; 355: 1518-1519 [PMID: 10801176 DOI: 10.1016/ S0140-6736(00)02169-3]
13. Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, Lampis R, Kryszak D, Cartenì M, Generoso M, Iafusco D, Prisco F, Laghi F, Riegler G, Carratu R, Counts D, Fasano A. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006; 55: 1443-1449 [PMID: 16644703 DOI: 10.2337/db05-1593]
14. Smecuol E, Sugai E, Niveloni S, Vázquez H, Pedreira S, Mazure R, Moreno ML, Label M, Mauriño E, Fasano A, Meddings J, Bai JC. Permeability, zonulin production, and enteropathy in dermatitis herpetiformis. Clin Gastroenterol Hepatol 2005; 3: 335-341 [PMID: 15822038 DOI: 10.1016/ S1542-3565(04)00778-5]
15. Zak-Gołąb A, Kocełak P, Aptekorz M, Zientara M, Juszczyk L, Martirosian G, Chudek J, Olszanecka-Glinianowicz M. Gut microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and normal weight subjects. Int J Endocrinol 2013; 2013: 674106 [PMID: 23970898 DOI: 10.1155/2013/674106]
16. Moreno-Navarrete JM, Sabater M, Ortega F, Ricart W, Fernández-Real JM. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-Associated insulin resistance. PLoS One 2012; 7: e37160 [PMID: 22629362 DOI: 10.1371/journal.pone.0037160]
17. Pacifico L, Martino MD, Catalano C, Panebianco V, Bezzi M, Anania C, Chiesa C. T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. World J Gastroenterol 2011; 17: 3012-3019 [PMID: 21799647]
18. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243 [PMID: 10797032 DOI: 10.1136/bmj.320.7244.1240]
19. Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS, Tamborlane WV, Caprio S. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004; 89: 1096-1101 [PMID: 15001593 DOI: 10.1210/jc.2003-031503]
20. Lê KA, Ventura EE, Fisher JQ, Davis JN, Weigensberg MJ, Punyanitya M, Hu HH, Nayak KS, Goran MI. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care 2011; 34: 485-490 [PMID: 21270204 DOI: 10.2337/dc10-0760]
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461]
22. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820 [PMID: 21319198 DOI: 10.1002/hep.24127]
23. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16 [PMID: 11296695 DOI: 10.1055/s-2001-12925]
24. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, Nardone G. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22: 471-476 [PMID: 22546554 DOI: 10.1016/ j.numecd]
25. Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013; 56: 461-468 [PMID: 23287807 DOI: 10.1016/j.numecd.2012.02.007]
26. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
27. Giorgio V, Miele L, Principessa L, Ferretti F, Villa MP, Negro V, Grieco A, Alisi A, Nobili V. Intestinal permeability is increased in children with non-Alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 2014; 46: 556-560 [PMID: 24631029 DOI: 10.1016/j.dld.2014.02.010]
28. Perrier C, Corthésy B. Gut permeability and food allergies. Clin Exp Allergy 2011; 41: 20-28 [PMID: 21070397 DOI: 10.1111/ j.1365-2222.2010.03639.x]
29. Salles Teixeira TF, Boroni Moreira AP, Silva Souza NC, Frias R, Gouveia Peluzio Mdo C. Intestinal permeability measurements: general aspects and possible pitfalls. Nutr Hosp 2014; 29: 269-281 [PMID: 24528342 DOI: 10.3305/nh.2014.29.2.7076]
30. Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 2004; 65: 259-265 [PMID: 14675058 DOI: 10.1111/j.1523-1755.2004.00351.x]
31. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486 [PMID: 12761248 DOI: 10.1097/01.ASN.0000068462.38661.89]